PITTSBURGH--(BUSINESS WIRE)--June 15, 1998--Mylan Laboratories
Inc. (NYSE:MYL) announced today that it has received approval from the
Food and Drug Administration to manufacture and market Sulfamylon(R)
Powder for 5% Topical Solution.
     This New Drug Application has orphan drug designation and is
indicated for use as an adjunctive topical antimicrobial agent to
control bacterial infection when used under moist dressings over
meshed autografts on excised burn wounds.
     The burn wound community is extremely pleased to have
Sulfamylon(R) added to their armamentarium of products.  This is the
first drug approved for this indication.
     Bertek Pharmaceuticals, the Branded Product Division of Mylan
Laboratories, will be responsible for the marketing of this exciting
new product.  Launch of Sulfamylon(R) is scheduled for July 15, 1998.